Ligachem Bio Announces ADC New Drug Research Results at World Lung Cancer Conference

[Financial News] Ligachem Bio announced on the 14th that it will present research results of its self-developed CEACAM5-antibody drug conjugate (ADC) 'LCB58A' at the World Conference on Lung Cancer (WCLC).
The WCLC conference will be held from the 6th to the 9th of next month in Barcelona, Spain. The related abstract has been published on the conference website.
LCB58A is a next-generation ADC candidate developed by combining the CEACAM5 antibody introduced from DaAn Biotherapeutics last February with its own ADC platform technology 'ConjuAll'.
According to the abstract, unlike existing CEACAM5-ADCs, LCB58A specifically binds only to cancer cells, not to soluble CEACAM5 present in the blood.
Clinically validated linker technology was also applied. Ligachem Bio conducted experiments on various ADCs with combinations of linkers and payloads across multiple cell lines. The experimental results showed superior internalization compared to the comparator antibody, tusamitamab. Additionally, it demonstrated antitumor efficacy in cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models.
A Ligachem Bio representative stated, "We have confirmed the potential to overcome the failures of previous CEACAM5-ADCs," and "We plan to accelerate development by submitting a global clinical trial plan (IND) in 2027."


kaya@fnnews.com Choi Hye-rim Reporter